PAD

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Friday, September 24, 2021 - 1:30pm

Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).

Key Points: 
  • Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • We will diligently advance the clinical development of RJX and evaluate its benefit for COVID-19 patients, said Fatih Uckun, MD PhD, the Chief Medical Officer of Reven.
  • It is currently being evaluated as a COVID-19 drug candidate in high risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

Vascular Surgeons are Embracing the Future of Peripheral Artery Disease (PAD) Treatment by Transitioning to Outpatient Procedures

Thursday, September 23, 2021 - 1:00pm

Dr. Correa joins three other Vascular Surgeons who have left their practices in the last year and a half to join Modern Vascular, joining one in St. Louis and two in Texas.

Key Points: 
  • Dr. Correa joins three other Vascular Surgeons who have left their practices in the last year and a half to join Modern Vascular, joining one in St. Louis and two in Texas.
  • Dr. Correa is not alone among vascular surgeons; four of the last seven Managing Physicians to come to Modern Vascular have also been Vascular Surgeons.
  • Modern Vascular clinics specialize in the treatment of peripheral artery disease (PAD) through below-the-knee and below-the-ankle and pedal endovascular arterial reconstruction.
  • Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

In Honor of National Peripheral Artery Disease (PAD) Awareness Month, THE SAGE GROUP Comments on the Costs and Consequences of the Amputation Lottery

Tuesday, September 14, 2021 - 2:41pm

It is commonly believed that amputation costs the hospital less than revascularization procedures.

Key Points: 
  • It is commonly believed that amputation costs the hospital less than revascularization procedures.
  • Although initial procedure costs are similar, total amputation costs including the costs of in-hospital mortality, morbidity and revision procedures are higher than those of either bypass or endovascular.
  • Treatment with MA (above-the-knee amputation or below-the-knee amputation) rather than revascularization significantly increases the economic burden of critical limb ischemia (CLI).
  • THE SAGE GROUP, a research and consulting company, specializes in peripheral vascular disease, including venous disease, PAD and CLI, as well as the economic costs of these diseases.

Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant

Tuesday, September 14, 2021 - 1:00pm

Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI.

Key Points: 
  • Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI.
  • Our recent funding puts us on the path towards that vision, said Juliana Elstad, CEO at Vibrato.
  • We are excited to partner with Vibrato Medical on the development of a truly novel technology to treat this terrible condition.
  • The company plans to use Series A funding and its $1.5M NIH grant for its pilot clinical study, to design and build its second-generation device, and advance its intellectual property.

The Worldwide Vascular Closure Devices Industry is Expected to Reach $2.7 Billion by 2026 - ResearchAndMarkets.com

Tuesday, September 7, 2021 - 11:38am

These advantages incorporate diminished draining difficulties, a decrease in post-procedural nursing care time required, expanded patient throughput, and quicker quiet ambulation.

Key Points: 
  • These advantages incorporate diminished draining difficulties, a decrease in post-procedural nursing care time required, expanded patient throughput, and quicker quiet ambulation.
  • Although there are various factors aiding the growth of the vascular closure devices market issues such as those with suture-based closure devices may affect this market growth.
  • Suture-based closure devices are increasingly being adopted by healthcare professionals for percutaneous closure of large-bore arteriotomies.
  • However, suture-based closure devices are cumbersome and are experiencing a downtick, owing to their long learning curve and increased risk of complications, which is expected to hurt the vascular closure device market during the forecast period.

R3 Vascular Reports the Initiation of Its First-In-Human Clinical Study

Thursday, September 2, 2021 - 9:42pm

R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.

Key Points: 
  • R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.
  • The R3 Vascular platform incorporates an innovative scaffold design and bioresorbable polymer technology resulting in biomechanical performance comparable to metallic stents.
  • At a 98-micron strut thickness across all its usable range of diameters, the MAGNITUDE BRS device is the thinnest BRS ever tested in this clinical setting.
  • Given the dire and unmet clinical need of patients presenting with CLI undergoing BTK revascularization, we are extremely pleased by the rapid progression of our program, said R3 Vascular CEO Kamal Ramzipoor .

Modern Vascular Raising Awareness of Peripheral Artery Disease and Preventing Amputations for PAD Awareness Month

Wednesday, September 1, 2021 - 2:00pm

PHOENIX, Sept. 1, 2021 /PRNewswire/ -- Modern Vascular, a pioneering medical group dedicated to preventing amputation through the outpatient treatment of Peripheral Artery Disease (PAD), is marking September PAD Awareness Month at its 16 nationwide clinics by offering screening and treatment for PAD.

Key Points: 
  • PHOENIX, Sept. 1, 2021 /PRNewswire/ -- Modern Vascular, a pioneering medical group dedicated to preventing amputation through the outpatient treatment of Peripheral Artery Disease (PAD), is marking September PAD Awareness Month at its 16 nationwide clinics by offering screening and treatment for PAD.
  • "At Modern Vascular, we want to make the suffering of unnecessary lower leg amputations a thing of the past so people can focus on living their normal lives."
  • Modern Vascular specializes in the treatment of peripheral artery disease (PAD) through below-the-knee, below-the-ankle, and pedal endovascular arterial reconstruction.
  • Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients.

Healogics® Raises Awareness of Peripheral Artery Disease (PAD) to Help Reduce Amputations

Wednesday, September 1, 2021 - 1:00pm

JACKSONVILLE, Fla., Sept. 1, 2021 /PRNewswire/ -- Healogics, the nation's leading provider of world-class wound care services, is raising awareness of Peripheral Artery Disease (PAD) throughout September.

Key Points: 
  • JACKSONVILLE, Fla., Sept. 1, 2021 /PRNewswire/ -- Healogics, the nation's leading provider of world-class wound care services, is raising awareness of Peripheral Artery Disease (PAD) throughout September.
  • Through this campaign, Healogics is supporting the American Heart Association's goal to reduce amputations by 20% by 2030 through increased PAD Awareness, diagnosis and treatment.
  • PAD affects nearly 10 million Americans and is a contributing factor in up to 30% of non-healing wounds on the lower leg.
  • As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country.

Imageware Biointellic Achieves Level 2 ISO Anti-Spoofing Compliance

Tuesday, August 31, 2021 - 1:30pm

Biointellic is a revolutionary zero-friction, anti-spoofing system designed to prevent intruders from breaching authentication systems.

Key Points: 
  • Biointellic is a revolutionary zero-friction, anti-spoofing system designed to prevent intruders from breaching authentication systems.
  • The intelligent presentation cyberattack detection solution is used in several Imageware offerings, including Imageware Authenticate, Imageware Proof, and the Imageware Identity Platform, as it provides passive PAD for face images using standard mobile phone cameras.
  • The rigorous Level 1 and 2 compliance testing conducted by iBeta included several advanced spoofing methods, including high-resolution pictures and videos, curved pictures with cut-out eyes, silicon masks, and mannequins.
  • Imageware is one of just a handful of vendors that have achieved Level 1 and Level 2 PAD certification with a passive solution.